PTC Therapeutics Gains Analyst Favor: Barclays Upgrade Fuels Valuation Debate Amid Rare Disease Focus
Barclays' upgrade of PTC Therapeutics to Overweight has spotlighted the biotech firm's valuation, with shares showing strong momentum but questions lingering over its path to profitability and reliance on a narrow drug portfolio.